A Phase 2 interventional study of Felzartamab and Placebo in Immunoglobulin A (IgA) Nephropathy, sponsored by HI-Bio, A Biogen Company. Completed at 59 sites in 15 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by HI-Bio, A Biogen Company (part of Biogen) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Glomerulonephritis, IGA with a site in Japan — 8 open to participants now, 15 under way, 12 of them phase 3. Glomerulonephritis, IGA · Japan.
Among the 22 studies in Glomerulonephritis, IGA with a site in Japan, this one is the 15th largest by enrollment, is one of 3 that started in 2021, is one of 7 in phase 2, and was the 9th registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.
Browse Glomerulonephritis, IGA studies →8 of the 22 studies in Glomerulonephritis, IGA with a site in Japan are open now. Recruiting first, the newest first:
argenx · Sites in Japan, United States
Ages 18+
Novartis Pharmaceuticals · Sites in Japan, United States, China and 5 more countries
Ages 2–18
Novartis Pharmaceuticals · Sites in Japan, United States, Brazil and 8 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Japan, United States, Argentina and 5 more countries
Ages 2–18
Alexion Pharmaceuticals, Inc. · Sites in Japan, United States, China and 4 more countries
Ages 2–18
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 13 · Phase 4 1
First in 2010; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 138 across the 22 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under HI-Bio, A Biogen Company, one of the names counted as Biogen. Under that name alone:
HI-Bio, A Biogen Company is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Biogen has 5 studies filed under Glomerulonephritis, IGA — fewer than ten, so there is no comparison to draw.
2 of the studies in Glomerulonephritis, IGA with a site in Japan that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06935357Phase 3BiogenA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | 2027-05-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Glomerulonephritis, IGA with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
Study Sponsor, originally HI-Bio, Inc., is now HI-Bio, A Biogen Company.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.
This study's enrollment of 54 is below the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Browse Glomerulonephritis, IGA studies →HI-Bio, A Biogen Company is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
First submitted before HI-Bio became part of Biogen.
Compared within Glomerulonephritis, IGA, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Kidney Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered felzartamab matching placebo as an intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 57, 85, 113 and 141.
Other: Placebo
Participants were administered felzartamab as an IV infusion based on their body weight on Days 1 and 15, and felzartamab matching placebo on Days 8, 22, 29, 57, 85, 113 and 141.
Drug: Felzartamab · Other: Placebo
Participants were administered felzartamab as an IV infusion based on their body weight on Days 1, 8,15, 29, and 57, and felzartamab matching placebo on Days 22, 85, 113 and 141.
Drug: Felzartamab · Other: Placebo
Participants were administered felzartamab as an IV infusion based on their body weight on Days 1,8,15, 22, 29, 57, 85, 113 and 141.
Drug: Felzartamab
Japanese participants were administered felzartamab as an IV infusion based on their body weight on Days 1,8,15, 22, 29, 57, 85, 113 and 141.
Drug: Felzartamab
anti-CD38+ monoclonal antibody
Also known as: MOR202
Placebo comparator
Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9
Proteinuria is high levels of protein in the urine and is measured by UPCR. Relative change in UPCR was estimated based on mixed effects model for repeated measure (MMRM) model. Least squares (LS) mean and standard error (SE) were reported. The reference proteinuria value before start of treatment is defined as the mean of the values determined at screening and prior to baseline (visit 2) predose (UPCR from 24h urine). Negative change from baseline indicates less proteinuria.
Time frame: Baseline, Month 9
Integrative Analysis of Several Endpoints: Percent Change From Baseline in Immunoglobulin A (IgA) Concentration by Predose Serum Concentration (Ctrough) Group
All felzartamab and placebo-treated participants with evaluable IgA data and felzartamab serum concentrations (in felzartamab-treated participants only) were divided into exposure quartiles using the sum of measurable felzartamab Ctrough values up to 9 months after the first dose. Percent change from baseline in IgA concentration in these participants was summarized as per each serum concentration quartile.
Time frame: Up to 9 months
Integrative Analysis of Several Endpoints: Maximum Serum Concentrations (Cmax) as Per the Infusion-Related Reactions (IRRs) After the First Dose
All participants with evaluable maximum felzartamab concentrations after the first dose were included in the analysis. Cmax values were assessed by infusion-related reaction status after the first dose.
Time frame: Up to 1 week
Part 1: Relative Change From Baseline in UPCR in 24-hour Urine at Months 3, 6, 12, 18 and 24
Proteinuria is high levels of protein in the urine and is measured by UPCR. Relative change in UPCR will be estimated based on an MMRM model. The reference proteinuria value before start of treatment is defined as the mean of the values determined at screening and prior to baseline (visit 2) predose (UPCR from 24h urine). Negative change from baseline indicates less proteinuria.
Time frame: Baseline, Months 3,6,12,18 and 24
Part 1: Number of Participants With Complete Response (CR) at Months 3, 6, 9, 12, 18 and 24
CR was defined as the reduction of proteinuria to less than 0.3 g/g UPCR, serum albumin within the reference range of the central laboratory and stable estimated glomerular filtration rate (eGFR) (at least 80% of value at baseline visit).
Time frame: Months 3,6,9,12,18 and 24
Part 1: Percentage of Participants With Response at Months 3, 6, 9, 12, 18 and 24
Response was defined as reduction of proteinuria to below 0.6 g/g (UPCR) and stable eGFR (at least 80% of value at baseline visit), but not CR.
Time frame: Months 3,6,9,12,18 and 24
Part 1: Albumin-Creatinine Ratio (ACR) at Months 6, 9, 12, 18 and 24
Time frame: Months 6, 9,12,18 and 24
Part 1: Duration of Response
Duration of response was defined as date of 1st observation of progressive disease minus date of 1st observation of response+1 day. Duration of response was estimated by Kaplan Meier method.
Time frame: Up to 2 years
Part 1: Time to Response
Time to response was defined as date of 1st observation of response minus date of randomization+1 day. Time to response was estimated by Kaplan Meier method.
Time frame: Up to 2 years
Change From Baseline in eGFR Over Time
eGFR was calculated as per the chronic kidney disease epidemiology collaboration (CKD-EPI) equation. eGFR =141×min(Scr/κ, 1)α×max(Scr κ,1)-1.209×0.993Age ×1.018\[if female\]×1.159 \[if black\] where: * Scr is serum creatinine in μmol/L, * κ is 61.9 for females and 79.6 for males, * α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1 eGFR as a measure of kidney function. eGFR was calculated in terms of milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2). A numerically smaller negative change in eGFR indicates a slowing in kidney disease progression.
Time frame: Baseline, Months 3,6,9,12,15,18, and 24
Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE)
TEAEs were defined as any AEs reported after the start of trial treatment until 28 days after the last trial treatment, defined as the treatment-emergent period. TESAEs were TEAEs that met the following criteria: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition.
Time frame: From the first dose until 28 days after last dose of study drug (up to 191 days)
Serum Concentrations of Felzartamab Over Time
Time frame: Predose and 30 minutes post-dose on Days 1, 15, 29; predose on Days 8, 57, 85, 113, 141; Post Treatment Days 169 and 267
Percentage of Participants With Anti- Felzartamab Antibodies
Blood samples were collected for measurement of anti-felzartamab antibodies in the serum. Number of participants with Anti-drug antibody (ADA) status positive/negative was summarized.
Time frame: From the first dose up to the end of the study (up to 2 years)
Participants were enrolled at investigative sites in Belgium, Bulgaria, Czechia, Georgia, Germany, Japan, Republic of Korea, Malaysia, Philippines, Serbia, Spain, Taiwan, Ukraine, and the United States from 31 August 2021 to 06 May 2024.
| Milestone | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 | Part 2: Japan Cohort |
|---|---|---|---|---|---|
| Started | 12 | 12 | 11 | 13 | 6 |
| Completed | 10 | 11 | 9 | 12 | 6 |
| Not completed | 2 | 1 | 2 | 1 | 0 |
| Withdrew: Investigator decision | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Requires prohibited medication | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal of consent | 1 | 1 | 1 | 0 | 0 |
Proteinuria is high levels of protein in the urine and is measured by UPCR. Relative change in UPCR was estimated based on mixed effects model for repeated measure (MMRM) model. Least squares (LS) mean and standard error (SE) were reported. The reference proteinuria value before start of treatment is defined as the mean of the values determined at screening and prior to baseline (visit 2) predose (UPCR from 24h urine). Negative change from baseline indicates less proteinuria.
| gram per gram (g/g) | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 |
|---|---|---|---|---|
| Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9 | -24.7 ± 19.43 | -16.5 ± 19.41 | -30.6 ± 21.72 | -38.5 ± 16.60 |
All felzartamab and placebo-treated participants with evaluable IgA data and felzartamab serum concentrations (in felzartamab-treated participants only) were divided into exposure quartiles using the sum of measurable felzartamab Ctrough values up to 9 months after the first dose. Percent change from baseline in IgA concentration in these participants was summarized as per each serum concentration quartile.
| percent change | All Felzartamab and Placebo-Treated Participants |
|---|---|
| Serum Concentration 0-180 µg/mL | -6.12 ± 15.0 |
| Serum Concentration 180-370 µg/mL | -14.1 ± 15.6 |
| Serum Concentration 370-850 µg/mL | -19.7 ± 22.7 |
| Serum Concentration >850 µg/mL | -26.1 ± 10.1 |
All participants with evaluable maximum felzartamab concentrations after the first dose were included in the analysis. Cmax values were assessed by infusion-related reaction status after the first dose.
| µg/mL | All Felzartamab-Treated Participants |
|---|---|
| Cmax in Participants With IRR | 445 ± 198 |
| Cmax in Participants Without IRR | 367 ± 131 |
Proteinuria is high levels of protein in the urine and is measured by UPCR. Relative change in UPCR will be estimated based on an MMRM model. The reference proteinuria value before start of treatment is defined as the mean of the values determined at screening and prior to baseline (visit 2) predose (UPCR from 24h urine). Negative change from baseline indicates less proteinuria.
| g/g | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 |
|---|---|---|---|---|
| Change at Month 3 | -18.0 ± 13.09 | -7.5 ± 13.47 | -35.1 ± 17.06 | -35.5 ± 14.57 |
| Change at Month 6 | -12.8 ± 20.85 | -29.3 ± 20.07 | -44.5 ± 23.32 | -43.9 ± 21.29 |
| Change at Month 12 | -3.9 ± 19.52 | 1.1 ± 19.49 | -44.4 ± 21.81 | -38.2 ± 19.02 |
| Change at Month 18 | -11.0 ± 23.40 | -24.9 ± 23.30 | -39.3 ± 25.54 | -48.3 ± 21.81 |
| Change at Month 24 | -38.1 ± 33.67 | -15.3 ± 34.24 | -30.9 ± 38.03 | -48.6 ± 32.19 |
CR was defined as the reduction of proteinuria to less than 0.3 g/g UPCR, serum albumin within the reference range of the central laboratory and stable estimated glomerular filtration rate (eGFR) (at least 80% of value at baseline visit).
| Participants | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 |
|---|---|---|---|---|
| Month 3 | 0 | 0 | 0 | 1 |
| Month 6 | 0 | 1 | 0 | 1 |
| Month 9 | 0 | 0 | 0 | 4 |
| Month 12 | 0 | 0 | 0 | 3 |
| Month 18 | 0 | 0 | 0 | 4 |
| Month 24 | 1 | 0 | 0 | 4 |
Response was defined as reduction of proteinuria to below 0.6 g/g (UPCR) and stable eGFR (at least 80% of value at baseline visit), but not CR.
| percentage of participants | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 |
|---|---|---|---|---|
| Month 3 | 8.3 | 9.1 | 0 | 44.4 |
| Month 6 | 0 | 9.1 | 0 | 55.6 |
| Month 9 | 9.1 | 0 | 11.1 | 8.3 |
| Month 12 | 9.1 | 0 | 22.2 | 27.3 |
| Month 18 | 0 | 0 | 22.2 | 16.7 |
| Month 24 | 0 | 11.1 | 12.5 | 20.0 |
| milligrams per gram (mg/g) | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 |
|---|---|---|---|---|
| Month 6 | 1.278 ± 0.8101 | 0.802 ± 0.4633 | 0.841 ± 0.7925 | 0.723 ± 1.0052 |
| Month 9 | 1.053 ± 0.7517 | 0.830 ± 0.3378 | 0.834 ± 0.4391 | 0.948 ± 1.1494 |
| Month 12 | 1.324 ± 0.7726 | 1.062 ± 0.5072 | 0.702 ± 0.4307 | 1.013 ± 1.5322 |
| Month 18 | 1.305 ± 0.9155 | 0.729 ± 0.3501 | 0.822 ± 0.6715 | 0.827 ± 0.9789 |
| Month 24 | 1.102 ± 0.8979 | 0.903 ± 0.5079 | 0.913 ± 0.6047 | 0.622 ± 0.9405 |
Duration of response was defined as date of 1st observation of progressive disease minus date of 1st observation of response+1 day. Duration of response was estimated by Kaplan Meier method.
| days | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 |
|---|---|---|---|---|
| Part 1: Duration of Response | 250 (78 to NA) | 140 (92 to NA) | 451 (NA to NA) | 188 (83 to NA) |
Time to response was defined as date of 1st observation of response minus date of randomization+1 day. Time to response was estimated by Kaplan Meier method.
| days | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 |
|---|---|---|---|---|
| Part 1: Time to Response | 767 (300 to NA) | NA (NA to NA) | NA (NA to NA) | 176 (85.0 to NA) |
eGFR was calculated as per the chronic kidney disease epidemiology collaboration (CKD-EPI) equation. eGFR =141×min(Scr/κ, 1)α×max(Scr κ,1)-1.209×0.993Age ×1.018\[if female\]×1.159 \[if black\] where: * Scr is serum creatinine in μmol/L, * κ is 61.9 for females and 79.6 for males, * α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1 eGFR as a measure of kidney function. eGFR was calculated in terms of milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2). A numerically smaller negative change in eGFR indicates a slowing in kidney disease progression.
| mL/min/1.73 m^2 | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 | Part 2: Japan Cohort |
|---|---|---|---|---|---|
| Change at Month 3 | -1.985 ± 7.5920 | 2.058 ± 4.9858 | 8.100 ± 18.1222 | 4.224 ± 8.3131 | 1.011 ± 6.3803 |
| Change at Month 6 | -8.163 ± 12.4166 | -2.560 ± 6.6112 | 3.914 ± 12.4652 | 0.033 ± 12.7546 | 0.296 ± 7.1089 |
| Change at Month 9 | -10.006 ± 9.3866 | -5.792 ± 7.3286 | 3.619 ± 11.2770 | -4.199 ± 15.8864 | -1.890 ± 2.9519 |
| Change at Month 12 | -8.299 ± 11.1636 | -4.618 ± 7.9684 | -0.747 ± 15.3308 | -4.198 ± 9.1530 | -8.959 ± 5.6681 |
| Change at Month 18 | -11.131 ± 9.7842 | -6.707 ± 8.4971 | 2.167 ± 11.0455 | -4.778 ± 11.7583 | — |
| Change at Month 24 | -9.550 ± 18.1470 | -7.394 ± 6.0913 | -3.342 ± 17.0161 | -6.210 ± 9.9485 | — |
TEAEs were defined as any AEs reported after the start of trial treatment until 28 days after the last trial treatment, defined as the treatment-emergent period. TESAEs were TEAEs that met the following criteria: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition.
| Participants | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 | Part 2: Japan Cohort |
|---|---|---|---|---|---|
| TEAE | 6 | 10 | 9 | 11 | 3 |
| TESAE | 0 | 1 | 1 | 0 | 0 |
| nanograms per milliliter (ng/mL) | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 | Part 2: Japan Cohort |
|---|---|---|---|---|
| Day 1: Predose | 67.9 ± 143.5 | 54.6 ± 28.2 | 50.0 ± 0.0 | 50.0 ± 0.0 |
| Day 1: 30 mins postdose | 204326.5 ± 3176.6 | 320616.0 ± 56.2 | 424347.7 ± 42.9 | 355517.2 ± 21.9 |
| Day 8: Predose | 123890.6 ± 34.3 | 111734.3 ± 17.7 | 119475.8 ± 29.9 | 119280.5 ± 35.6 |
| Day 15: Predose | 58680.3 ± 39.6 | 73299.3 ± 136.9 | 242622.8 ± 14.9 | 217362.3 ± 21.7 |
| Day 15: 30 mins postdose | 479855.1 ± 27.8 | 564030.0 ± 14.5 | 726082.1 ± 18.0 | 579946.2 ± 19.9 |
| Day 29: Predose | 93782.5 ± 40.0 | 142190.5 ± 28.3 | 156053.1 ± 777.0 | 339770.3 ± 39.1 |
| Day 29: 30 mins postdose | 94110.3 ± 42.2 | 471802.8 ± 29.7 | 868596.5 ± 30.2 | 696420.5 ± 22.7 |
| Day 57: Predose | 5243.4 ± 1663.5 | 70569.7 ± 68.4 | 126530.5 ± 40.1 | 132181.4 ± 69.6 |
| Day 85: Predose | 69.6 ± 153.0 | 21010.4 ± 3668.4 | 55920.7 ± 89.4 | 69524.7 ± 96.5 |
| Day 113: Predose | 74.6 ± 199.2 | 849.3 ± 2399.8 | 28697.5 ± 209.5 | 63543.2 ± 95.0 |
| Day 141: Predose | 74.3 ± 194.4 | 50.0 ± 0.0 | 59744.8 ± 50.9 | 18172.1 ± 9900.0 |
| Post Treatment Day 169 | 64.8 ± 104.8 | 50.0 ± 0.0 | 48355.6 ± 109.3 | 35243.0 ± 194.3 |
| Post Treatment Day 267 | 72.8 ± 176.5 | 50.0 ± 0.0 | 50.0 ± 0.0 | 50.0 ± 0.0 |
Blood samples were collected for measurement of anti-felzartamab antibodies in the serum. Number of participants with Anti-drug antibody (ADA) status positive/negative was summarized.
| Participants | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 | Part 2: Japan Cohort |
|---|---|---|---|---|---|
| Positive (Post-baseline Visits) | 1 | 6 | 3 | 3 | 1 |
| Negative (Post-baseline Visits) | 11 | 6 | 7 | 10 | 5 |
Collected over From signing of informed consent up to the end of the study (up to 24 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Placebo | 0/12 (0%) | 1/12 (8.3%) | 9/12 (75%) |
| Part 1: Felzartamab Dosing Arm M1 | 0/12 (0%) | 1/12 (8.3%) | 11/12 (91.7%) |
| Part 1: Felzartamab Dosing Arm M2 | 0/11 (0%) | 1/11 (9.1%) | 9/11 (81.8%) |
| Part 1: Felzartamab Dosing Arm M3 | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| Part 2: Japan Cohort | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 | Part 2: Japan Cohort |
|---|---|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 0/12 | 0/12 | 1/11 | 0/13 | 0/6 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/12 | 1/12 | 0/11 | 0/13 | 0/6 |
| Dedifferentiated liposarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/12 | 0/12 | 0/11 | 0/13 | 0/6 |
| Event | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 | Part 2: Japan Cohort |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 3/12 | 4/12 | 2/11 | 6/13 | 2/6 |
| NasopharyngitisInfections and infestations | 1/12 | 1/12 | 3/11 | 2/13 | 1/6 |
| Upper respiratory tract infectionInfections and infestations | 0/12 | 2/12 | 2/11 | 1/13 | 0/6 |
| ToothacheGastrointestinal disorders | 0/12 | 0/12 | 2/11 | 0/13 | 0/6 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/12 | 1/12 | 2/11 | 2/13 | 1/6 |
| DizzinessNervous system disorders | 1/12 | 0/12 | 2/11 | 0/13 | 0/6 |
| CellulitisInfections and infestations | 0/12 | 0/12 | 0/11 | 0/13 | 1/6 |
| PharyngitisInfections and infestations | 0/12 | 0/12 | 0/11 | 0/13 | 1/6 |
| Abdominal discomfortGastrointestinal disorders | 0/12 | 0/12 | 0/11 | 0/13 | 1/6 |
| VomitingGastrointestinal disorders | 2/12 | 0/12 | 1/11 | 0/13 | 0/6 |
All enrolled participants included all randomized participants from the full analysis set (FAS) plus all Japanese participants who were enrolled in Part 2. The FAS included participants randomized to Part 1 of the study.
| Age, Continuous(years) | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 | Part 2: Japan Cohort | Total |
|---|---|---|---|---|---|---|
| Mean | 39.6 ± 11.84 | 47.4 ± 10.41 | 35.1 ± 14.31 | 39.2 ± 7.20 | 51.7 ± 14.19 | 41.6 ± 12.30 |
| Sex: Female, Male(Participants) | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 | Part 2: Japan Cohort | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 6 | 3 | 3 | 3 | 18 |
| Male | 9 | 6 | 8 | 10 | 3 | 36 |
| Race/Ethnicity, Customized(Participants) | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 | Part 2: Japan Cohort | Total |
|---|---|---|---|---|---|---|
| Race — White | 9 | 6 | 9 | 9 | 0 | 33 |
| Race — American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 1 |
| Race — Asian | 3 | 5 | 2 | 4 | 6 | 20 |
| Race/Ethnicity, Customized(Participants) | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 | Part 2: Japan Cohort | Total |
|---|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 1 | 1 | 0 | 2 | 0 | 4 |
| Ethnicity — Not Hispanic or Latino | 11 | 8 | 8 | 8 | 6 | 41 |
| Ethnicity — Not Reported | 0 | 2 | 3 | 3 | 0 | 8 |
| Ethnicity — Unknown | 0 | 1 | 0 | 0 | 0 | 1 |
| Urine Protein to Creatinine Ratio (UPCR)(gram per gram (g/g)) | Part 1: Placebo | Part 1: Felzartamab Dosing Arm M1 | Part 1: Felzartamab Dosing Arm M2 | Part 1: Felzartamab Dosing Arm M3 | Part 2: Japan Cohort | Total |
|---|---|---|---|---|---|---|
| Mean | 2.04 ± 1.158 | 1.57 ± 0.742 | 1.76 ± 0.828 | 1.69 ± 1.301 | 1.02 ± 0.324 | 1.68 ± 0.999 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
Ran from Aug 2021 to primary completion in Feb 2023, 17 months.
Results were first posted in Apr 2026, 3 years 2 months after primary completion. A results delay was requested in Feb 2024.
Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Felzartamab